The mRNA Revolution Gains Traction Against a Fading Enemy The U. S. FDA's approval of Moderna's mRNA based flu shot marks a significant milestone in the fight against influenza, a disease that has long plagued humanity.
The approval is particularly noteworthy given the agency's earlier reluctance to review the application. Moderna's mFlusiva shot offers a 26.
6 percent boost in efficacy over traditional vaccines, which have historically struggled to protect vulnerable populations against flu.